Tuesday, October 18, 2016

Synalar


Synalar is a brand name of fluocinolone topical, approved by the FDA in the following formulation(s):


SYNALAR (fluocinolone acetonide - cream; topical)



  • Manufacturer: MEDIMETRIKS PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.01% [RLD][AT], 0.025% [RLD][AT], 0.025% [RLD][AT]

SYNALAR (fluocinolone acetonide - ointment; topical)



  • Manufacturer: MEDIMETRIKS PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.025% [RLD][AT]

SYNALAR (fluocinolone acetonide - solution; topical)



  • Manufacturer: MEDIMETRIKS PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.01% [RLD][AT]

Has a generic version of Synalar been approved?


Yes. The following products are equivalent to Synalar:


fluocinolone acetonide cream; topical



  • Manufacturer: FOUGERA

    Approval date: December 16, 1982

    Strength(s): 0.01% [AT], 0.025% [AT]


  • Manufacturer: G AND W LABS

    Approval date: July 26, 1988

    Strength(s): 0.01% [AT], 0.025% [AT]


  • Manufacturer: TARO

    Approval date: April 27, 1982

    Strength(s): 0.025% [AT]

fluocinolone acetonide ointment; topical



  • Manufacturer: FOUGERA

    Approval date: December 16, 1982

    Strength(s): 0.025% [AT]


  • Manufacturer: G AND W LABS

    Approval date: July 26, 1988

    Strength(s): 0.025% [AT]


  • Manufacturer: TARO

    Approval date: September 15, 1994

    Strength(s): 0.025% [AT]

fluocinolone acetonide solution; topical



  • Manufacturer: FOUGERA

    Approval date: December 16, 1982

    Strength(s): 0.01% [AT]


  • Manufacturer: TARO

    Approval date: September 11, 1985

    Strength(s): 0.01% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Synalar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Synalar.

See also...

  • Synalar Consumer Information (Drugs.com)
  • Synalar Cream Consumer Information (Wolters Kluwer)
  • Synalar Solution Consumer Information (Wolters Kluwer)
  • Synalar Consumer Information (Cerner Multum)
  • Synalar Advanced Consumer Information (Micromedex)
  • Synalar Mild Advanced Consumer Information (Micromedex)
  • Synalar Regular Advanced Consumer Information (Micromedex)
  • Fluocinolone Cream Consumer Information (Wolters Kluwer)
  • Fluocinolone Oil Consumer Information (Wolters Kluwer)
  • Fluocinolone Oil (Body Oil) Consumer Information (Wolters Kluwer)
  • Fluocinolone Oil (Scalp Oil) Consumer Information (Wolters Kluwer)
  • Fluocinolone Shampoo Consumer Information (Wolters Kluwer)
  • Fluocinolone Solution Consumer Information (Wolters Kluwer)
  • Fluocinolone topical Consumer Information (Cerner Multum)
  • Fluocinolone topical oil Consumer Information (Cerner Multum)
  • Fluoderm Mild Cream Advanced Consumer Information (Micromedex)
  • Fluoderm Mild Ointment Advanced Consumer Information (Micromedex)
  • Fluoderm Regular Cream Advanced Consumer Information (Micromedex)
  • Fluoderm Regular Ointment Advanced Consumer Information (Micromedex)
  • Fluolar Mild Advanced Consumer Information (Micromedex)
  • Fluolar Regular Advanced Consumer Information (Micromedex)
  • Fluonide Mild-Cream Advanced Consumer Information (Micromedex)
  • Synamol Advanced Consumer Information (Micromedex)
  • Fluocinolone Topical application Advanced Consumer Information (Micromedex)
  • Fluocinolone Acetonide topical AHFS DI Monographs (ASHP)
  • Fluocinonide topical AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Isordil


Isordil is a brand name of isosorbide dinitrate, approved by the FDA in the following formulation(s):


ISORDIL (isosorbide dinitrate - tablet; oral)



  • Manufacturer: VALEANT INTL

    Approval date: July 29, 1988

    Strength(s): 10MG [AB], 20MG [AB], 30MG [RLD][AB], 40MG [RLD], 5MG [AB]

Has a generic version of Isordil been approved?


Yes. The following products are equivalent to Isordil:


isosorbide dinitrate tablet; oral



  • Manufacturer: PAR PHARM

    Approval date: March 12, 1987

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: PAR PHARM

    Approval date: October 2, 1987

    Strength(s): 20MG [AB]


  • Manufacturer: PAR PHARM

    Approval date: January 12, 1988

    Strength(s): 30MG [AB]


  • Manufacturer: SANDOZ

    Approval date: January 7, 1988

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: SANDOZ

    Approval date: April 7, 1988

    Strength(s): 20MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: January 6, 1988

    Strength(s): 5MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: January 7, 1988

    Strength(s): 10MG [AB]


  • Manufacturer: WEST WARD

    Approval date: October 29, 1987

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: WEST WARD

    Approval date: November 2, 1987

    Strength(s): 20MG [AB]


  • Manufacturer: WEST WARD

    Approval date: January 10, 2007

    Strength(s): 30MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isordil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Isordil.

See also...

  • Isordil Advanced Consumer Information (Micromedex)
  • Isosorbide Dinitrate Consumer Information (Wolters Kluwer)
  • Isosorbide Dinitrate Extended-Release Consumer Information (Wolters Kluwer)
  • Isosorbide dinitrate Consumer Information (Cerner Multum)
  • Apo-Isdn Advanced Consumer Information (Micromedex)
  • Isosorbide dinitrate Oral, Sublingual Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Topamax


Topamax is a brand name of topiramate, approved by the FDA in the following formulation(s):


TOPAMAX (topiramate - capsule; oral)



  • Manufacturer: JANSSEN PHARMS

    Approval date: October 26, 1998

    Strength(s): 15MG [AB], 25MG [RLD][AB]

TOPAMAX (topiramate - tablet; oral)



  • Manufacturer: JANSSEN PHARMS

    Approval date: December 24, 1996

    Strength(s): 100MG [AB], 200MG [AB], 25MG [RLD][AB], 50MG [AB]

Has a generic version of Topamax been approved?


A generic version of Topamax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Topamax and have been approved by the FDA:


topiramate capsule; oral



  • Manufacturer: MYLAN

    Approval date: October 14, 2009

    Strength(s): 15MG [AB], 25MG [AB]


  • Manufacturer: SANDOZ

    Approval date: October 14, 2009

    Strength(s): 15MG [AB], 25MG [AB]


  • Manufacturer: TEVA

    Approval date: April 17, 2009

    Strength(s): 15MG [AB], 25MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: April 15, 2009

    Strength(s): 15MG [AB], 25MG [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: October 14, 2009

    Strength(s): 15MG [AB], 25MG [AB]

topiramate tablet; oral



  • Manufacturer: ACCORD HLTHCARE

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: APOTEX INC

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: CIPLA LTD

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: INVAGEN PHARMS

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: RANBAXY

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB]


  • Manufacturer: SUN PHARM INDS LTD

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: TEVA

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: TORRENT PHARMS

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: UNICHEM

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: UPSHER SMITH

    Approval date: January 7, 2010

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WOCKHARDT USA

    Approval date: September 1, 2010

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: March 27, 2009

    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Treatment of migraine
    Patent 5,998,380
    Issued: December 7, 1999
    Inventor(s): Ehrenberg; Bruce L. & Wagner; Anita K.
    Assignee(s): New England Medical Center Hospitals, Inc.
    A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula: ##STR1##
    Patent expiration dates:

    • October 13, 2015
      ✓ 
      Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE


    • April 13, 2016
      ✓ 
      Pediatric exclusivity




  • Migraine treatment method using topiramate and related compounds
    Patent 6,503,884
    Issued: January 7, 2003
    Inventor(s): Bruce L.; Ehrenberg & Anita K.; Wagner
    Assignee(s): New England Medical Center Hospitals, Inc.
    A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:
    Patent expiration dates:

    • October 13, 2015
      ✓ 
      Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE


    • April 13, 2016
      ✓ 
      Pediatric exclusivity




  • Treatment of migraine
    Patent 7,018,983
    Issued: March 28, 2006
    Inventor(s): Ehrenberg; Bruce L. & Wagner; Anita K.
    Assignee(s): New England Medical Center Hospitals, Inc.
    A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:
    Patent expiration dates:

    • October 13, 2015
      ✓ 
      Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE


    • April 13, 2016
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition of topiramate
    Patent 7,125,560
    Issued: October 24, 2006
    Inventor(s): Thakur; Madhav S. & Kotwal; Pramod M. & Gibbs; Irwin S.
    Assignee(s): Ortho-McNeil Pharmaceutical, Inc.
    The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.
    Patent expiration dates:

    • March 1, 2019
      ✓ 
      Patent use: TREATMENT OF SEIZURES


    • September 1, 2019
      ✓ 
      Pediatric exclusivity




  • Treatment of migraine
    Patent 7,498,311
    Issued: March 3, 2009
    Inventor(s): Ehrenberg; Bruce L. & Wagner; Anita K.
    Assignee(s): New England Medical Center Hospitals, Inc.
    A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:
    Patent expiration dates:

    • October 13, 2015
      ✓ 
      Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE


    • April 13, 2016
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 22, 2012 - INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL

    • June 22, 2013 - PEDIATRIC EXCLUSIVITY

See also...

  • Topamax Consumer Information (Drugs.com)
  • Topamax Consumer Information (Wolters Kluwer)
  • Topamax Sprinkle Capsules Consumer Information (Wolters Kluwer)
  • Topamax Consumer Information (Cerner Multum)
  • Topamax Advanced Consumer Information (Micromedex)
  • Topamax AHFS DI Monographs (ASHP)
  • Topiramate Consumer Information (Wolters Kluwer)
  • Topiramate Sprinkle Capsules Consumer Information (Wolters Kluwer)
  • Topiramate Consumer Information (Cerner Multum)
  • Topiramate Advanced Consumer Information (Micromedex)
  • Topiramate AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Treximet


Treximet is a brand name of naproxen/sumatriptan, approved by the FDA in the following formulation(s):


TREXIMET (naproxen sodium; sumatriptan succinate - tablet; oral)



  • Manufacturer: GLAXOSMITHKLINE

    Approval date: April 15, 2008

    Strength(s): 500MG;EQ 85MG BASE [RLD]

Has a generic version of Treximet been approved?


No. There is currently no therapeutically equivalent version of Treximet available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Treximet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
    Patent 6,060,499
    Issued: May 9, 2000
    Inventor(s): Plachetka; John R.
    Assignee(s): Pozen, Inc.
    This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.
    Patent expiration dates:

    • August 14, 2017
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product




  • Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
    Patent 6,586,458
    Issued: July 1, 2003
    Inventor(s): John R.; Plachetka
    Assignee(s): Pozen Inc.
    The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.
    Patent expiration dates:

    • August 14, 2017
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product




  • Multilayer dosage forms containing NSAIDs and triptans
    Patent 7,332,183
    Issued: February 19, 2008
    Inventor(s): Plachetka; John R. & Kothapalli; Venkata Markandeya & Gilbert; Donna L.
    Assignee(s): Pozen Inc.
    The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.
    Patent expiration dates:

    • October 2, 2025
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product




  • Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
    Patent 8,022,095
    Issued: September 20, 2011
    Inventor(s): Plachetka; John R.
    Assignee(s): Pozen, Inc.
    The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.
    Patent expiration dates:

    • August 14, 2017
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 15, 2011 - NEW COMBINATION

See also...

  • Treximet Consumer Information (Drugs.com)
  • Treximet Consumer Information (Wolters Kluwer)
  • Treximet Consumer Information (Cerner Multum)
  • Treximet Advanced Consumer Information (Micromedex)
  • Sumatriptan/Naproxen Consumer Information (Wolters Kluwer)
  • Sumatriptan and naproxen Consumer Information (Cerner Multum)
  • Sumatriptan and naproxen Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Topicort LP


See also: Generic Topicort


Topicort LP is a brand name of desoximetasone topical, approved by the FDA in the following formulation(s):


TOPICORT LP (desoximetasone - cream; topical)



  • Manufacturer: TARO PHARMS NORTH

    Approved Prior to Jan 1, 1982

    Strength(s): 0.05% [AB]

Has a generic version of Topicort LP been approved?


No. There is currently no therapeutically equivalent version of Topicort LP available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topicort LP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Topicort LP.

See also...

  • Topicort LP Cream Consumer Information (Wolters Kluwer)
  • Topicort LP Consumer Information (Cerner Multum)
  • Topicort LP Advanced Consumer Information (Micromedex)
  • Desoximetasone Cream Consumer Information (Wolters Kluwer)
  • Desoximetasone Gel Consumer Information (Wolters Kluwer)
  • Desoximetasone topical Consumer Information (Cerner Multum)
  • Desoxi Advanced Consumer Information (Micromedex)
  • Taro-Desoximetasone Advanced Consumer Information (Micromedex)
  • Desoximetasone Topical application Advanced Consumer Information (Micromedex)
  • Desoximetasone AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Triglide


Triglide is a brand name of fenofibrate, approved by the FDA in the following formulation(s):


TRIGLIDE (fenofibrate - tablet; oral)



  • Manufacturer: SKYEPHARMA AG

    Approval date: May 7, 2005

    Strength(s): 50MG

Has a generic version of Triglide been approved?


No. There is currently no therapeutically equivalent version of Triglide available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triglide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Spray drying process and compositions of fenofibrate
    Patent 6,696,084
    Issued: February 24, 2004
    Inventor(s): Gary W.; Pace & Awadesh K.; Mishra & Robert A.; Snow & Indu; Parikh & Pol-Henri W.; Guivarc'h
    Assignee(s): RTP Pharma Inc.
    The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.
    Patent expiration dates:

    • September 11, 2021
      ✓ 
      Patent use: A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
      ✓ 
      Drug substance
      ✓ 
      Drug product



See also...

  • Triglide Consumer Information (Cerner Multum)
  • Triglide Advanced Consumer Information (Micromedex)
  • Fenofibrate Consumer Information (Drugs.com)
  • CIP - Fenofibrate Consumer Information (Wolters Kluwer)
  • Fenofibrate Consumer Information (Wolters Kluwer)
  • Fenofibrate Consumer Information (Cerner Multum)
  • Fenofibrate Advanced Consumer Information (Micromedex)
  • Fenofibrate AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Trizivir


Trizivir is a brand name of abacavir/lamivudine/zidovudine, approved by the FDA in the following formulation(s):


TRIZIVIR (abacavir sulfate; lamivudine; zidovudine - tablet; oral)



  • Manufacturer: VIIV HLTHCARE

    Approval date: November 14, 2000

    Strength(s): EQ 300MG BASE;150MG;300MG [RLD]

Has a generic version of Trizivir been approved?


No. There is currently no therapeutically equivalent version of Trizivir available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trizivir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Therapeutic nucleosides
    Patent 5,034,394
    Issued: July 23, 1991
    Inventor(s): Daluge; Susan M.
    Assignee(s): Burroughs Wellcome Co.
    The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
    Patent expiration dates:

    • December 18, 2011
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 18, 2012
      ✓ 
      Pediatric exclusivity




  • Crystalline oxathiolane derivatives
    Patent 5,905,082
    Issued: May 18, 1999
    Inventor(s): Roberts; Tony Gordon & Evans; Paul
    Assignee(s): Glaxo Group Limited
    (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
    Patent expiration dates:

    • May 18, 2016
      ✓ 
      Patent use: TREATMENT OF HIV
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • November 18, 2016
      ✓ 
      Pediatric exclusivity




  • Carbocyclic nucleoside hemisulfate and its use in treating viral infections
    Patent 6,294,540
    Issued: September 25, 2001
    Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
    Assignee(s): Glaxo Wellcome Inc.
    The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
    Patent expiration dates:

    • May 14, 2018
      ✓ 
      Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • November 14, 2018
      ✓ 
      Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
      ✓ 
      Pediatric exclusivity




  • Synergistic combinations of zidovudine, 1592U89 and 3TC
    Patent 6,417,191
    Issued: July 9, 2002
    Inventor(s): David Walter; Barry & Martha Heider; St. Clair
    Assignee(s): GlaxoSmithKline
    The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
    Patent expiration dates:

    • March 28, 2016
      ✓ 
      Patent use: TREATMENT OF HIV
      ✓ 
      Drug product



See also...

  • Trizivir Consumer Information (Drugs.com)
  • Trizivir Consumer Information (Wolters Kluwer)
  • Trizivir Consumer Information (Cerner Multum)
  • Trizivir Advanced Consumer Information (Micromedex)
  • Abacavir/Lamivudine/Zidovudine Consumer Information (Wolters Kluwer)
  • Abacavir, lamivudine, and zidovudine Consumer Information (Cerner Multum)
  • Abacavir-lamivudine-zidovudine Consumer Information (Cerner Multum)
  • Abacavir, lamivudine, and zidovudine Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)